Uniqure

Yahoo Finance • 3 days ago

William Blair Maintains Market Perform Rating on uniQure (QURE) Despite AMT-130 Approval Uncertainty

uniQure N.V. (NASDAQ:QURE) ranks among the most oversold biotech stocks to invest in. William Blair reaffirmed its Market Perform rating for uniQure N.V. (NASDAQ:QURE) on November 11 while the company anticipates comments from regulators r... Full story

Yahoo Finance • 4 days ago

QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

RADNOR, Pa., Nov. 24, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDA... Full story

Yahoo Finance • 9 days ago

Summers Value Partners Established a Position in UniQure N.V. (QURE) in Q3

Summers Value Partners, an investment management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Summers Value Fund LP returned a net return of 20.4% net in Q3 2025, surpassing the... Full story

Yahoo Finance • 11 days ago

Wall Street Has a Positive Outlook on uniQure N.V. (QURE) Despite Challenges From The FDA

​uniQure N.V. (NASDAQ:QURE) is one of the Hottest Small Cap Stocks to Buy Now. Wall Street has a positive outlook on uniQure N.V. (NASDAQ:QURE) despite the regulatory challenges from the FDA for its experimental gene therapy called AMT-130... Full story

Yahoo Finance • 14 days ago

QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

RADNOR, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDA... Full story

Yahoo Finance • 16 days ago

QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm

LOS ANGELES, Nov. 12, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of uniQure N.V. (“uniQure” or “the Company”) (NASDAQ: QUR... Full story

Yahoo Finance • 16 days ago

uniQure (QURE) Surges 17.9% Ahead of 2 Health Conferences

We recently published 10 Stocks on a Hot Streak. uniQure NV (NASDAQ:QURE) is one of the best-performing stocks on Tuesday. uniQure soared by 17.93 percent on Tuesday to close at $30.84 apiece as investors repositioned portfolios ahead of... Full story

Yahoo Finance • 18 days ago

uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update

~ Announced pivotal topline data from Phase I/II study of AMT-130 in Huntington’s disease met its primary and key secondary endpoints, demonstrating statistically significant slowing of disease progression at 36 months and supportive trend... Full story

Yahoo Finance • 21 days ago

NASDAQ: QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

RADNOR, Pa., Nov. 07, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDA... Full story

Yahoo Finance • 22 days ago

uniQure to Announce Third Quarter 2025 Financial Results

LEXINGTON, Mass. and AMSTERDAM, Nov. 06, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report third quarter 2025 financ... Full story

Yahoo Finance • 23 days ago

UNIQURE ALERT: Bragar Eagel & Squire, P.C. is Investigating uniQure N.V. on Behalf of uniQure Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In uniQure (QURE) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in uniQure and would like to disc... Full story

Yahoo Finance • 24 days ago

uniQure N.V. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors (QURE)

NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against uniQure N.V. (“uniQure” or the “Company”) (NASDAQ:QURE). The investigation concerns whether the Company and/or memb... Full story

Yahoo Finance • 25 days ago

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

LEXINGTON, Mass. and AMSTERDAM, Nov. 03, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it received fee... Full story

Yahoo Finance • 2 months ago

Advanced Viral Delivery Systems Revolutionizing Gene Therapy for Neurological Disorders

Dublin, Oct. 06, 2025 (GLOBE NEWSWIRE) -- The "Gene Therapy on Neurological Diseases Market Report 2025" has been added to ResearchAndMarkets.com's offering. The gene therapy on neurological diseases market size has grown rapidly in... Full story

Yahoo Finance • 2 months ago

uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

LEXINGTON, Mass. and AMSTERDAM, Sept. 29, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its... Full story

Yahoo Finance • 2 months ago

uniQure announces pricing of upsized $300M public offering

* uniQure N.V. (NASDAQ:QURE [https://seekingalpha.com/symbol/QURE]) announced on Thursday the pricing of its previously announced underwritten public offering [https://seekingalpha.com/pr/20245492-uniqure-announces-pricing-of-upsized-300... Full story

Yahoo Finance • 2 months ago

uniQure Announces Pricing of Upsized $300 Million Public Offering

LEXINGTON, Mass. and AMSTERDAM, Sept. 25, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its... Full story

Yahoo Finance • 2 months ago

Stocks making the biggest moves midday: Mirion Technologies, Freeport-McMoRan, CarMax & more

Check out the companies making the biggest moves midday: Mirion Technologies — The radiation detection name fell more than 8% after it announced a common stock offering of $300 million. Mirion is also selling $250 million in convertible bo... Full story

Yahoo Finance • 2 months ago

Uniqure (QURE) Soars 275% on Stellar Clinical Trial for Huntington’s Disease

We recently published 10 Stocks Crushing Wall Street, AI Stocks Dominate. Uniqure NV (NASDAQ:QURE) is one of the top performers on Tuesday. Shares of Uniqure NV soared by as much as 275 percent on Wednesday to hit a new all-time high as i... Full story

Yahoo Finance • 2 months ago

Stocks making the biggest premarket moves: Intel, Oracle, Lithium Americas, Opendoor and more

Check out the companies making the biggest moves in premarket trading: Oracle — The database software company fell 3% as worries around the AI trade continue to drag the stock lower. Rothschild & Co Redburn initiated coverage of Oracle wit... Full story